Kinase inhibitors

Question 1

Abemaciclib

Answer 1

CDK4/6 inhibitor - breast cancer

Question 2

Acalabrutinib

Answer 2

Bruton’s tyrosine kinase

Used in CLL, SLL, mantle cell lymphoma

ADR - AF/aflutter, transient lymphocytosis, increased bleeding from platelet dysfunction

Question 3

Afatinib

Answer 3

EGFR, HER2, HER4 receptor inhibitor

Question 4

Alectinib

Answer 4

ALK receptor

For ALK-positive NSCLC

Question 5

Axitinib

Answer 5

VEGF receptor inhibitor

Question 6

Baricitinib

Answer 6

JAK 1 and JAK2 inhibitor

Used for RA, atopic dermatitis, COVID
Do not use in severe renal impairment

Question 7

Binimetinib

Answer 7

Mitogen-activated extracellular kinases (MEK) 1 + 2

Used in melanoma

Question 8

Brigatinib

Answer 8

ALK receptor, ROS1

NSCLC

Question 9

Carbozatinib

Answer 9

Hepatocyte growth factor receptor (HGFR, c-Met), VEGFR type 2, AXL

Used in HCC and advanced RCC

Question 10

Ceritinib

Answer 10

ALK receptor

Question 11

Cobimetinib

Answer 11

MEK1, MEK2

Question 12

Crizotinib

Answer 12

ALK receptor, c-Met, ROS1

Question 13

Dabrafinib

Answer 13

BRAF including V600E and V600K

Question 14

Dasatinib

Answer 14

BCR-ABL1, Src family, stem cell factor receptor, PDGFR

Used in CML, phil chromosome positive ALL

Question 15

Encorafenib

Answer 15

BRAF inhibitor

Question 16

Entrectinib

Answer 16

Tropomysin receptor tyrosine kinase, ROS1, ALK receptor

Question 17

Erlotinib

Answer 17

EGFR

Used in NSCLC, pancreatic Ca

Question 18

Gefitinib

Answer 18

EGFR

Question 19

Ibrutinib

Answer 19

BTK

Used for CLL, SLL, mantle cell lymphoma, Waldenstrom macoglobulinaemia

Question 20

Idelalisib

Answer 20

PI3K inhibitor

Question 21

Imatinib

Answer 21

BCR-ABL1, c-Kit, PDGFR

Used in CML, GIST, phil chromosome positive ALL, MDS

Question 22

Lapatinib

Answer 22

EGFR, HER2

Question 23

Lenvatinib

Answer 23

VEGFR types 1-3, fibroblast growth factor types 1-4, PDGFR, c-Kit, RET

Question 24

Lorlatinib

Answer 24

ALK receptor, ROS1

Question 25

Midostaurin

Answer 25

VEGFR type 2, PDGFR, c-Kit, FLT-3, protein kinase C Used in AML, advanced systemic mastocytosis

Question 26

Nilotinib

Answer 26

BCR-ABL1, c-Kit, ephrin receptor, PDGFR Used in CML

Question 27

Nintedanib

Answer 27

VEGFR types 1-3, PDGFR, FGFR types 1-3 Used in IPF

Question 28

Osimertinib

Answer 28

EGFR including T790M mutation Used in NSCLC

Question 29

Palbociclib

Answer 29

CDK4/6 inhibtor

Question 30

Pazopanib

Answer 30

VEGFR types 1-3, PDGFR, c-Kit

Question 31

Ponatinib

Answer 31

BCR-ABL1, c-Kit, PLT-3, RET

Question 32

Regorafenib

Answer 32

VEGFR types 1-3, PDGFR, c-Kit, RET

Question 33

Ribociclib

Answer 33

CDK4/6 inhibitor Used in advanced or metastatic breast cancer

Question 34

Ruxolitinib

Answer 34

JAK 1, JAK2 Used in myelofibrosis, PCV

Question 35

Sorafenib

Answer 35

VEGFR types 2-3, PDGFR, c-Kit, FLT-3 Used in RCC, HCC, thyroid carcinoma

Question 36

Sunitinib

Answer 36

VEGFR types 1-3, PDGFR, c-Kit, FLT-3

Question 37

Tofacitinib

Answer 37

JAK1, JAK2, JAK3

Question 38

Trametinib

Answer 38

MEK1, MEK2

Question 39

Upadacitinib

Answer 39

JAK1 Used in RA, psoriatic arthritis, ankylosing spondylitis

Question 40

Vandetanib

Answer 40

VEGFR types 2-3, EGFR, RET

Question 41

Vemurafenib

Answer 41

BRAF V600E and V600K Used in metastatic melanoma with BRAF V600E mutation